Applying Artificial Intelligence to Identify Subphenotypes of Acute Kidney Injury in Mexican Patients With Severe COVID-19 (IA-COVAKI)

June 20, 2024 updated by: Elizabeth Santiago Del Angel, Instituto Nacional de Enfermedades Respiratorias
The goal of this observational study was to identify subphenotypes of acute kidney injury patients with COVID-19, and the investigators analyzed their impact on mortality. The study included demographic and clinical variables of the participants. The implementation of Machine Learning algorithms and Artificial Intelligence methods are used, and some specific implementations were designed for the analysis, where each group was characterized by traditional statistical methods.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

2934

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Mexico
      • Mexico City, Mexico, 14080
        • Instituto Nacional De Enfermedades Respiratorias

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with acute kidney injury and COVID-19

Description

Inclusion Criteria:

  • Patients older than 15 years old, hospitalized, and with severe acute respiratory syndrome (SARS-CoV-2) positive confirmation.

Exclusion Criteria:

  • Patients who did not have at least 1 creatinine measurement.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Subphenotypes of acute kidney injury in patients
Time Frame: Through study completion, an average of one month
Number of acute kidney injury subphenotypes in patients with COVID-19
Through study completion, an average of one month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mortality of acute kidney injury patients
Time Frame: Through study completion, an average of one month
Differences between mortality rates in acute kidney injury subphenotypes of patients with COVID-19
Through study completion, an average of one month
Severity of acute kidney injury patients
Time Frame: Through study completion, an average of one month
Differences between severity stages in acute kidney injury subphenotypes of patients with COVID-19
Through study completion, an average of one month
Non-recovery in acute kidney injury patients
Time Frame: Through study completion, an average of one month
Differences between non recovery rates in acute kidney injury subphenotypes of patients with COVID-19
Through study completion, an average of one month
Renal replacement therapy requirement in acute kidney injury patients
Time Frame: Through study completion, an average of one month
Differences between renal replacement therapy requirement rates in acute kidney injury subphenotypes of patients with COVID-19
Through study completion, an average of one month
Length of stay of acute kidney injury patients
Time Frame: Through study completion, an average of one month
Differences in-hospital length of stay in acute kidney injury subphenotypes of patients with COVID-19.
Through study completion, an average of one month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Instituto Nacional de Enfermedades Respiratorias

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 18, 2024

Primary Completion (Actual)

June 18, 2024

Study Completion (Actual)

June 18, 2024

Study Registration Dates

First Submitted

June 18, 2024

First Submitted That Met QC Criteria

June 20, 2024

First Posted (Actual)

June 24, 2024

Study Record Updates

Last Update Posted (Actual)

June 24, 2024

Last Update Submitted That Met QC Criteria

June 20, 2024

Last Verified

June 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • C38-23

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19

Clinical Trials on clusters

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe